Document is current
Any future updates will be listed below
-
Authors
Jones, Daniel
Benson, Neil
Roashan, Emily
Isner, Jean-Charles
Salem, Omar
Seal, Claire J
Russell, Roslin
Marshall, Sylwia
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04740424 at ClinicalTrials.govDocuments that mention this clinical trial
668 FS222 is a CD137/PD-L1 tetravalent, bispecific antibody which elicits robust pharmacodynamic activity in advanced solid tumor patients in a FIH study
https://doi.org/10.1136/jitc-2024-sitc2024.0668
First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.2505
- License Information
